JPRN-jRCT2080222501已完成1 期
A PHASE I, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC AND EFFICACY STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS,
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 142
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Provided written informed consent for treatment.
- •2. 20 years of age or older at enrollment.
- •3. Histologically or cytologically confirmed advanced or metastatic solid tumor(s) without standard treatment remains.
- •4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 on time of patient's allocation.
排除标准
- •1. A serious illness or medical conditions.
- •2. Known hypersensitivity to any drugs similar to TAS-120 in structure or class.
- •3. Pregnant or lactating female or women of child-bearing potential who have a positive pregnancy test (urine or serum) within 7 days prior to starting the study drug.
研究者
相似试验
已完成
1 期
A PHASE I, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, PHARMACOKINETIC, AND EFFICACY STUDY OF TAS-117 IN PATIENTS WITH ADVANCED SOLID TUMORSPatients with advanced solid tumors, ovarian clear cell carcinoma and endometrial cancer.JPRN-jRCT2080222728Taiho Pharmaceutical Co., Ltd.168
未知
1 期
A PHASE I, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, PHARMACOKINETIC, AND EFFICACY STUDY OF TAS-121 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)SCLCJPRN-jRCT2080222600Taiho Pharmaceutical Co., Ltd.
已完成
不适用
A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of TAS-119 in Patients with Advanced Solid Tumoursoncologysolid tumors10027655NL-OMON47320Taiho Oncology Inc.40
进行中（未招募）
不适用
A phase 1 dose-escalating study for CT-P27 on its own and in combination with TamifluDiseases of th respiratory systemKCT0001617Celltrion36
已完成
1 期
Intramuscular inactivated rabies vector platform Corona Virus Vaccine (rDNA-BBV151)CTRI/2021/08/035425Bharat Biotech International Limited150